Primary liver cancer, metastatic liver cancer, benign liver disease
Conditions
Interventions
ICG 25 mg/vial dissolved in 10 ml of the accompanying water for injection as a base (or further diluted with an appropriate amount of saline) is injected intravenously or topically into the intrahepat
Sponsors
Toho University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients whose preoperative diagnosis is primary liver cancer, metastatic liver cancer, or benign hepatic disease to be treated by hepatic resection. 2) Patients whose general condition and hepatic reserve are judged by the responsible or collaborating physicians to be sufficient to tolerate the operation. 3) Patients must be at least 20 years of age at the time consent is obtained. 4) The patient must have been given a written explanation of the procedure and his/her written consent must have been obtained.
Exclusion criteria
Exclusion criteria: 1) Patients with a history of allergy to ICG. (2) Patients with a history of allergy to iodine-based contrast media. 3) Patients with a serious allergy history. (4) Adults with impaired judgment. (5) Adults who are unconscious. (6) Patients who need to be considered for the disclosure of the disease. (7) Other cases that the investigator or sub-investigator deems inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy and safety in the identification of anatomical territory of section or segment during the liver resection Accuracy and safety in the identification of liver tumors during the liver resection | — |
Secondary
| Measure | Time frame |
|---|---|
| Operative duration Blood loss Postoperative hospital stay Postoperative morbidity | — |
Countries
Japan
Contacts
Public ContactOtsuka Yichiro
Omori Hospital, Toho University Medical Center Department of Surgery, General and Gastroenterological surgery
Outcome results
None listed